| N = 29 |
---|---|
Symptoms—n (%) |  |
 Fatigue | 25 (86%) |
 Muscle pain | 18 (62%) |
 Dyspnea | 14 (48%) |
 Inappropriate sinus tachycardia | 9 (31%) |
 Low-grade fever | 9 (31%) |
Functional status | Â |
 Grade 0 | 0 (0%) |
 Grade I—n (%) | 7 (24%) |
 Grade II—n (%) | 8 (27.5%) |
 Grade III—n (%) | 5 (17.2%) |
 Grade IV—n (%) | 9 (31%) |
Median number of days until evaluation days (IQR) | 57 (42–71) |
Median number of days to extra-respiratory positive RT- PCR (IQR) | 55 (39–67) |
SARS-CoV-2 IgG tests—n (%) | 25 (86%) |
Hemoglobin (g/dL)—median (IQR) | 14.3 (13.2–15) |
Lymphocyte count (× 10E3/µl)—median (IQR) | 1.4 (1.2–1.7) |
Platelet count (× 10E3/µL)—median (IQR) | 202 (184–238) |
Serum creatinine (mg/dL)—median (IQR) | 0.72 (0.63–0.82) |
Alanin aminotransferase (U/L)—median (IQR) | 24 (20–39.5) |
  > 40 U/L—n (%) | 7 (25%) |
  ≤ 40 U/L—n (%) | 21 (75%) |
Ferritin (µg/L)—median (IQR) | 100 (38.5–204) |
  > 205 (µg/L)—n (%) | 7 (25%) |
  ≤ 205 (µg/L)—n (%) | 21 (75%) |
Positive SARS-CoV-2 RT-PCR | Â |
 Plasma—n (%) | 13 (44.8%) |
 Stool—n (%) | 5 (17.2%) |
 Urine—n (%) | 4 (13.7%) |
 At least one positive result—n (%) | 15 (51.7%) |
 Two positive results—n (%) | 5 (17,2%) |
 Three positive results—n (%) | 2 (6.8%) |